#1 Clinical Trials Search in Europe

Kpl-404

KPL-404, also known as abiprubart, is a humanized monoclonal antibody being studied in clinical trials for its potential in treating rheumatoid arthritis. These trials aim to assess the safety, effectiveness, and how the body processes this new drug. The studies involve both healthy volunteers and patients with moderate to severe rheumatoid arthritis who haven’t responded well to other treatments.

Table of Contents

What is KPL-404?

KPL-404 is a new medication being studied for the treatment of rheumatoid arthritis (RA). It is classified as a humanized monoclonal antibody, which means it’s a type of protein made in a laboratory that mimics antibodies naturally produced by our immune system[1]. This medication is designed to target specific parts of the immune system that are involved in causing rheumatoid arthritis symptoms.

How KPL-404 Works

While the exact mechanism of KPL-404 is not fully described in the available information, as a monoclonal antibody, it likely works by targeting and blocking specific proteins or cells in the immune system that contribute to inflammation and joint damage in rheumatoid arthritis. This targeted approach is different from some other RA treatments that may affect the entire immune system[1].

Potential Benefits for Rheumatoid Arthritis Patients

KPL-404 is being studied for patients with moderate to severe active rheumatoid arthritis who haven’t responded well to other treatments. Specifically, it’s being tested in patients who have had an inadequate response or are intolerant to:

  • Janus kinase inhibitors (JAKi): These are a type of medication that work inside cells to reduce inflammation.
  • Biologic disease-modifying anti-rheumatic drugs (bDMARDs): These are advanced treatments that target specific parts of the immune system[1].

The goal of KPL-404 treatment is to reduce disease activity in rheumatoid arthritis patients. This is measured using a score called the Disease Activity Score of 28 Joints Using C-reactive Protein (DAS28-CRP), which assesses how active the RA is based on examining 28 specific joints and a blood test for inflammation[1].

Current Clinical Trials

KPL-404 is currently being studied in clinical trials to determine its safety and effectiveness. There are two main studies underway:

  1. Phase 2 Study for Rheumatoid Arthritis: This is a larger study looking at how well KPL-404 works for RA patients. It’s a 28-week study that includes a 12-week treatment period and a 12-week follow-up period. The study is comparing different doses of KPL-404 to a placebo (a substance with no active medication) to see how well it works and how safe it is[1].

  2. Phase 1 Study in Healthy Volunteers: This study is testing KPL-404 in people without rheumatoid arthritis to understand how the drug behaves in the body and to check for any potential side effects. This type of study is important for determining safe dosages and understanding how the medication is processed by the body[2].

How KPL-404 is Administered

KPL-404 is being tested in two main ways of administration:

  • Subcutaneous (SC) injection: This means the medication is injected just under the skin. In the clinical trials, it’s being given every 1, 2, or 4 weeks, depending on the dose[1].
  • Intravenous (IV) infusion: This method involves giving the medication directly into a vein. This is being tested in the Phase 1 study[2].

Safety and Side Effects

As with any new medication, understanding the safety and potential side effects of KPL-404 is a crucial part of the ongoing clinical trials. The researchers are carefully monitoring for any Treatment-Emergent Adverse Events (TEAEs), which are any unfavorable and unintended signs, symptoms, or diseases that occur during the treatment period[1][2].

It’s important to note that as KPL-404 is still in the testing phase, not all potential side effects may be known. The ongoing studies will help to identify any safety concerns and determine the most appropriate dosing regimen.

If you’re interested in learning more about KPL-404 or potentially participating in a clinical trial, it’s crucial to discuss this with your rheumatologist or healthcare provider. They can provide more information and help determine if this experimental treatment might be appropriate for your specific situation.

Aspect Details
Drug Name KPL-404 (abiprubart)
Drug Type Humanized monoclonal antibody
Condition Studied Rheumatoid Arthritis
Trial Phases Phase 1 (healthy volunteers), Phase 2 (RA patients)
Administration Routes Intravenous (IV) and Subcutaneous (SC)
Main Study Objectives Safety, Pharmacokinetics, Pharmacodynamics, Efficacy
Key Outcome Measures Treatment-Emergent Adverse Events (TEAEs), DAS28-CRP score
Study Duration Up to 28 weeks (Phase 2 study)

FAQ

  • What is KPL-404? KPL-404 is a humanized monoclonal antibody being studied as a potential treatment for rheumatoid arthritis. It's designed to target specific parts of the immune system involved in the disease process.
  • What types of clinical trials are being conducted with KPL-404? There are two main types of trials: a Phase 1 study with healthy volunteers to test safety and how the body processes the drug, and a Phase 2 study with rheumatoid arthritis patients to assess safety and effectiveness.
  • How is KPL-404 administered in these trials? KPL-404 is being tested in both intravenous (IV) and subcutaneous (SC) forms. The subcutaneous form is injected under the skin, while the intravenous form is given directly into a vein.
  • Who can participate in the KPL-404 clinical trials? The Phase 1 trial involves healthy volunteers. The Phase 2 trial includes patients with moderate to severe rheumatoid arthritis who haven't responded well to or couldn't tolerate at least one biologic disease-modifying anti-rheumatic drug or a Janus kinase inhibitor.
  • What are the main goals of these clinical trials? The main goals are to evaluate the safety of KPL-404, understand how the body processes the drug (pharmacokinetics), and assess its effectiveness in treating rheumatoid arthritis symptoms.

Ongoing Clinical Trials on Kpl-404

  • Study on the Effects of Abiprubart for Patients with Sjögren’s Disease

    Not recruiting

    2 1
    Investigated drugs:
    Czechia France Germany Hungary Poland Spain

Glossary

  • Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells. In this case, KPL-404 is a monoclonal antibody designed to target specific parts of the immune system involved in rheumatoid arthritis.
  • Rheumatoid Arthritis (RA): A chronic inflammatory disorder that can affect more than just your joints. In some people, the condition can damage a wide variety of body systems, including the skin, eyes, lungs, heart and blood vessels.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including how it's absorbed, distributed, metabolized, and excreted.
  • Pharmacodynamics (PD): The study of the biochemical and physiological effects of drugs on the body and how these effects relate to the drug's concentration.
  • Disease-modifying anti-rheumatic drug (DMARD): A class of drugs used in the treatment of rheumatoid arthritis that work to modify the course of the disease, rather than just treating symptoms.
  • Janus kinase inhibitor (JAKi): A type of medication that works by inhibiting the activity of one or more of the Janus kinase family of enzymes, which play a role in inflammation and immune function.
  • DAS28-CRP: Disease Activity Score of 28 Joints using C-reactive Protein. It's a measure used to assess the activity of rheumatoid arthritis, considering 28 specific joints and a blood test for inflammation.
  • Treatment-Emergent Adverse Events (TEAEs): Any unfavorable and unintended sign, symptom, or disease that emerges or worsens after starting a medical treatment, whether or not it's considered related to the treatment.

References

  1. https://clinicaltrials.gov/study/NCT05198310
  2. https://clinicaltrials.gov/study/NCT04497662